Asunto(s)
Citalopram/efectos adversos , Trasplante de Corazón , Trasplante de Hígado , Actividad Motora/efectos de los fármacos , Inhibidores Selectivos de la Recaptación de Serotonina/efectos adversos , Discinesia Tardía/inducido químicamente , Humanos , Masculino , Recuperación de la Función , Factores de Riesgo , Discinesia Tardía/diagnóstico , Discinesia Tardía/fisiopatología , Resultado del Tratamiento , Adulto JovenRESUMEN
INTRODUCTION: Abulia is defined as a pathological state of amotivation, apathy, and global absence of willpower. It presents with a challenging array of overlapping symptoms, making effective identification and treatment difficult. CASE PRESENTATION: We describe the first known report of an adolescent with a ventricular assist device who developed abulia following a left middle cerebral artery (MCA) stroke who responded successfully to treatment with olanzapine. DISCUSSION: The neurobiological etiology of abulia is still unclear but is postulated to be related to deficits in the dopaminergic reward circuitry in the frontal-subcortical-mesolimbic regions. There have been reports of poststroke patients with abulia being treated by modulating this dopamine circuitry and in some cases with short-term low-dose olanzapine. CONCLUSION: Further research is needed to develop a better understanding of the pathophysiology of abulia leading to more effective treatment algorithms including more specific diagnostic tools and effective pharmacological interventions.